Moreover, cryopreserved GPRC5D targeting CAR-engineered NK cells retained comparable antigen-specific cytotoxicity in vitro and demonstrated the capacity to reduce tumor burden in an antigen-dependent manner in the xenograft model. This evidence concerns the gene GPRC5D and neoplasm.